Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer

N. M. Tiffany, E. M. Wersinger, Mark Garzotto, Tomasz (Tom) Beer

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Objectives To determine the safety and efficacy of zoledronic acid (Zometa) combined with imatinib mesylate (Gleevec) in patients with bone pain due to androgen-independent prostate cancer. Methods Fifteen patients were treated with zoledronic acid 4 mg intravenously every 28 days and imatinib mesylate 400 mg/day. The pain response, defined as a 2-point reduction in the Present Pain Intensity Scale or normalization if the initial score was 1, was the primary endpoint. Secondary endpoints included palliative response, prostate-specific antigen response, measurable disease response, time to progression, impact on quality of life, decrease in markers of bone turnover, and tolerability of the drug combination. Results The study was stopped early because of a lack of activity. No palliative or clinical activity was detected for the combination, and no prostate-specific antigen responses were observed. The median time to progression was 4 weeks (95% confidence interval 3 to 5), and the median duration of treatment was 8 weeks (range 1.6 to 16.7). The median overall survival was 54 weeks (95% confidence interval 18 to 90). Therapy was associated with a reduction in urine N-telopeptides and a trend toward a reduction in serum osteocalcin, but no change occurred in bone-specific alkaline phosphatase. Conclusions In this patient population, imatinib mesylate and zoledronic acid produced no prostate-specific antigen responses and had no palliative or clinical activity.

Original languageEnglish (US)
Pages (from-to)934-939
Number of pages6
JournalUrology
Volume63
Issue number5
DOIs
StatePublished - May 2004

Fingerprint

zoledronic acid
Androgens
Prostatic Neoplasms
Prostate-Specific Antigen
Pain
Confidence Intervals
Bone and Bones
Bone Remodeling
Osteocalcin
Drug Combinations
Reaction Time
Alkaline Phosphatase
Quality of Life
Urine
Safety
Survival
Imatinib Mesylate
Therapeutics
Serum

ASJC Scopus subject areas

  • Urology

Cite this

Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer. / Tiffany, N. M.; Wersinger, E. M.; Garzotto, Mark; Beer, Tomasz (Tom).

In: Urology, Vol. 63, No. 5, 05.2004, p. 934-939.

Research output: Contribution to journalArticle

@article{66b00ca1d7874e8fa393e3bf79d109e0,
title = "Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer",
abstract = "Objectives To determine the safety and efficacy of zoledronic acid (Zometa) combined with imatinib mesylate (Gleevec) in patients with bone pain due to androgen-independent prostate cancer. Methods Fifteen patients were treated with zoledronic acid 4 mg intravenously every 28 days and imatinib mesylate 400 mg/day. The pain response, defined as a 2-point reduction in the Present Pain Intensity Scale or normalization if the initial score was 1, was the primary endpoint. Secondary endpoints included palliative response, prostate-specific antigen response, measurable disease response, time to progression, impact on quality of life, decrease in markers of bone turnover, and tolerability of the drug combination. Results The study was stopped early because of a lack of activity. No palliative or clinical activity was detected for the combination, and no prostate-specific antigen responses were observed. The median time to progression was 4 weeks (95{\%} confidence interval 3 to 5), and the median duration of treatment was 8 weeks (range 1.6 to 16.7). The median overall survival was 54 weeks (95{\%} confidence interval 18 to 90). Therapy was associated with a reduction in urine N-telopeptides and a trend toward a reduction in serum osteocalcin, but no change occurred in bone-specific alkaline phosphatase. Conclusions In this patient population, imatinib mesylate and zoledronic acid produced no prostate-specific antigen responses and had no palliative or clinical activity.",
author = "Tiffany, {N. M.} and Wersinger, {E. M.} and Mark Garzotto and Beer, {Tomasz (Tom)}",
year = "2004",
month = "5",
doi = "10.1016/j.urology.2003.12.022",
language = "English (US)",
volume = "63",
pages = "934--939",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer

AU - Tiffany, N. M.

AU - Wersinger, E. M.

AU - Garzotto, Mark

AU - Beer, Tomasz (Tom)

PY - 2004/5

Y1 - 2004/5

N2 - Objectives To determine the safety and efficacy of zoledronic acid (Zometa) combined with imatinib mesylate (Gleevec) in patients with bone pain due to androgen-independent prostate cancer. Methods Fifteen patients were treated with zoledronic acid 4 mg intravenously every 28 days and imatinib mesylate 400 mg/day. The pain response, defined as a 2-point reduction in the Present Pain Intensity Scale or normalization if the initial score was 1, was the primary endpoint. Secondary endpoints included palliative response, prostate-specific antigen response, measurable disease response, time to progression, impact on quality of life, decrease in markers of bone turnover, and tolerability of the drug combination. Results The study was stopped early because of a lack of activity. No palliative or clinical activity was detected for the combination, and no prostate-specific antigen responses were observed. The median time to progression was 4 weeks (95% confidence interval 3 to 5), and the median duration of treatment was 8 weeks (range 1.6 to 16.7). The median overall survival was 54 weeks (95% confidence interval 18 to 90). Therapy was associated with a reduction in urine N-telopeptides and a trend toward a reduction in serum osteocalcin, but no change occurred in bone-specific alkaline phosphatase. Conclusions In this patient population, imatinib mesylate and zoledronic acid produced no prostate-specific antigen responses and had no palliative or clinical activity.

AB - Objectives To determine the safety and efficacy of zoledronic acid (Zometa) combined with imatinib mesylate (Gleevec) in patients with bone pain due to androgen-independent prostate cancer. Methods Fifteen patients were treated with zoledronic acid 4 mg intravenously every 28 days and imatinib mesylate 400 mg/day. The pain response, defined as a 2-point reduction in the Present Pain Intensity Scale or normalization if the initial score was 1, was the primary endpoint. Secondary endpoints included palliative response, prostate-specific antigen response, measurable disease response, time to progression, impact on quality of life, decrease in markers of bone turnover, and tolerability of the drug combination. Results The study was stopped early because of a lack of activity. No palliative or clinical activity was detected for the combination, and no prostate-specific antigen responses were observed. The median time to progression was 4 weeks (95% confidence interval 3 to 5), and the median duration of treatment was 8 weeks (range 1.6 to 16.7). The median overall survival was 54 weeks (95% confidence interval 18 to 90). Therapy was associated with a reduction in urine N-telopeptides and a trend toward a reduction in serum osteocalcin, but no change occurred in bone-specific alkaline phosphatase. Conclusions In this patient population, imatinib mesylate and zoledronic acid produced no prostate-specific antigen responses and had no palliative or clinical activity.

UR - http://www.scopus.com/inward/record.url?scp=2342565080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2342565080&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2003.12.022

DO - 10.1016/j.urology.2003.12.022

M3 - Article

C2 - 15134984

AN - SCOPUS:2342565080

VL - 63

SP - 934

EP - 939

JO - Urology

JF - Urology

SN - 0090-4295

IS - 5

ER -